DSP Clinical President And Founder Darlene Panzitta Named To The PharmaVOICE 100 List Of The Most Influential People In Life Sciences Industries
Ms. Panzitta Called a Champion for Small Pharmaceutical Companies That Lack the Resources to Conduct Their Own Clinical Studies
PARSIPPANY, N.J.--(BUSINESS WIRE)--DSP Clinical announced that President and Founder Darlene Panzitta is among this year’s PharmaVOICE 100 most influential people in life sciences.
“I’m honored that my colleagues chose me as one of this year’s PharmaVOICE 100. It’s a reflection of our team’s 100% commitment to bringing world-class clinical study management expertise and customer service to small biopharmaceutical, life science and medical device companies.”
DSP provides customer-focused, results-driven Contract Research Services for pharmaceutical and device companies conducting Phase I-IV clinical studies.
Established eight years ago by PharmaVOICE magazine, the PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the life sciences industry.
Darlene Panzitta is an award-winning pharmaceutical executive with over 15 years’ experience in drug development and clinical trial management. Since she founded DSP in 1999, the company has earned a national reputation for excellence in clinical trial management and customer service.
Ms. Panzitta continues to earn accolades for her vision and focus on raising the bar in outsourced clinical trial management. In addition to the PharmaVOICE 100, this year Ms. Panzitta led DSP Clinical to a place on the Women Presidents Organization and American Express OPEN list of the 50 fastest growing North American companies owned or led women.
Darlene Panzitta said, “I’m honored that my colleagues chose me as one of this year’s PharmaVOICE 100. It’s a reflection of our team’s 100% commitment to bringing world-class clinical study management expertise and customer service to small biopharmaceutical, life science and medical device companies.”
About DSP Clinical
DSP is a full service CRO that manages Phase I-IV clinical studies for pharmaceutical, biotech, and device companies from study set-up through FDA submission. DSP helps clients get drugs to market faster with an aggressive management style and use of a fixed-cost monthly billing model. Services include study management, site monitoring, investigator site management, data management, biostatistics, study rescue, site and monitor training/auditing, medical writing, and FDA submissions. Services are flexible and DSP can provide an à la carte approach to complement clients’ clinical experience, resources, and staff. For more information, visit www.dspclinical.com. Follow DSP Clinical Research on Facebook and Twitter.
Source: DSP Clinical
Copyright Business Wire 2012